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Abstract
Purpose: To evaluate the efficacy and toxicity of helical tomotherapy (HT) in the management of spine chordomas
when proton therapy is unavailable or non-feasible.
Methods and materials: Between 2007 and 2013, 30 patients with biopsy-proven chordomas were treated by HT
in five French institutions. Information regarding local control (LC), overall survival (OS), progression-free survival
(PFS) and metastasis-free survival (MFS) was collected. Clinical efficacy, toxicity and treatment quality were
evaluated.
Results: Two-year actuarial LC, OS, PFS and MFS were 69.9%, 96.7%, 61.2% and 76.4%, respectively. HT treatments
were well tolerated and no Grade 4–5 toxicities were observed. HT permitted the delivery of a mean dose of 68 Gy
while respecting organ at risk (OAR) dose constraints, in particular in the spinal cord and cauda equina.
Conclusions: This multicentric, retrospective study demonstrated the feasibility of HT in the treatment of spine
chordomas, in the absence of hadron therapy.
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Introduction
Chordomas are rare cancers, representing 1–4% of
primary bone cancers, with a global incidence of 8.4 in
10 million persons [1]. Chordomas are aggressive tumors
with a strong tendency to recur locally after surgical
resection and with a known resistance to radiotherapy
and chemotherapy [2]. Radical en bloc resection with
healthy tissue margins is currently the preferred treat-
ment as it delivers best local control (LC) rates. How-
ever, this procedure is rarely possible because of the
proximity of the tumor to neurological structures (spinal
cord, cauda equina, nerve roots) or infiltration in soft
tissue and vasculo-nervous axis or digestive and urinary
system vicinity [3].
High-dose radiation therapy (RT), in particular proton
and carbon ion therapy, leads to an increase in LC of
the disease [4–6]. Unfortunately, these techniques
remain very costly and are not readily available. Helical
tomotherapy (HT) is a RT technique that combines
intensity modulated RT (IMRT) and image guided RT
(IGRT), thereby allowing dose escalation to the tumor
while reducing doses to adjacent organs at risk (OARs).
HT has shown, in our experience, dosimetric advantages
to other forms of IMRT as it allows for steeper dose
gradients at the border of the tumor than other radiation
delivery techniques.
We report here the results of a French multicentric,
retrospective study in which we address the technical
feasibility, treatment quality and toxicity of HT in the
treatment of 30 spinal cord and sacral chordomas.
National recommendations for clinical indication target
volume and OAR definitions were previously detailed
and published before this study [7, 8].
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Primary objective of the study was to assess the LC of
the disease. Secondary objectives were overall survival
(OS), progression-free survival (PFS), metastasis-free




This study was performed with the permission of the
Consultative Commission of the Treatment of Information
in Research for Health (CCTIRS, Comité Consultatif sur le
Traitement de l’Information en matière de Recherche
dans le domaine de la Santé) and the National Com-
mission of Information Technology and Freedom
(CNIL, Commission Nationale de l’Informatique et des
Libertés). Institutional Board approvals were also ob-
tained. The study was performed in the context of a
national program, previously defined and published [7, 8].
Patient selection
Between 2007 and 2013, 30 patients diagnosed with
biopsy-proven non-metastatic chordoma of mobile spine
and sacrum were treated with HT in 5 different compre-
hensive cancer centers (Institut Bergonié Comprehensive
Cancer Center, Bordeaux n = 14; René Gauducheau Com-
prehensive Cancer Center, Nantes n = 7; Paul Strauss
Comprehensive Cancer Center, Strasbourg n = 6; Hôpital
de la Pitié-Salpêtrière-Charles-Foix, Paris n = 2; Oscar
Lambret, Comprehensive Cancer Center, Lille n = 1).
Tomotherapy
When planning radiation therapy, Tomotherapy offered
advantages over other techniques including IMRT,
VMAT for clues of conformity, homogeneity and cover-
age. Furthermore, it facilitated a better dose gradient
compared to other techniques, allowing maximum re-
duction of the dose to OARs. Hence, it was chosen as
the preferred IMRT technique and all participating
centers used the same Tomotherapy equipment. HT was
performed by a Tomotherapy accelerator (Accuray® Inc.)
using IMRT and IGRT techniques and 6 MV photons.
Treatment planning used a dose calculation algorithm
based on the convolution of pre-calculated photon
kernels [9] and a dose optimization algorithm based on
χ 2 minimization [10, 11]. Daily Megavoltage Computed
Tomography (MVCT) was performed for patient posi-
tioning. Magnetic Resonance Imaging (MRI) examina-
tions were used to define the target volume. Margins
from Clinical Target Volume to Planning Target Vol-
umes (PTVs) used were 3 or 5 mm. Nine tomotherapy
plans with a simultaneous integrated boost technique
were delivered.
Statistical analysis
The analysis of survival rates was performed using the
STATA v.11 software (Stata Corp., College Station, TX).
The median follow-up of the series was calculated ac-
cording to the inverse Kaplan-Meier method [12], with
the deaths being censored [13]. OS, LC, PFS and MFS
were calculated using the Kaplan-Meier method. OS was
based on the date of first histological diagnosis to the
date of analysis or time to death. LC, PFS and MFS were
based on the date of the start of the tomotherapy.
Simulation of proton therapy plans
Proton dosimetry plans were calculated with the treat-
ment planning system Eclipse v.11 (Varian Medical
Systems, Palo Alto, CA). The fluence of spot-scanning
beams was optimized using the algorithm developed by
Lomax [7] and the dose was calculated with a pencil
beam convolution-superposition algorithm [6]. As treat-
ment planning with protons does not require the use of
opposed beams as in the case of photon beam therapy,
we tried to reduce the number of beams as much as
possible. In a total of 29 proton dosimetries (28 patients,
one with a separate boost), 17 proton plans had 2 fields,
8 plans had 3 fields, 4 plans had 4 fields and one plan
had 6 fields. All proton plans had at least two fields to
reduce the dose to the skin, a third field was introduced
to compensate for the more complicated anatomies (for
better OAR sparing), and finally, 4 or more fields were
necessary in the case of osteosynthesis material within
the target volume to further homogenize the dose
distribution.
Dosimetric data collection
All dosimetric data were collected according to the
International Commission on Radiation Units and Mea-
surements, ICRU 83 criteria [14]. For the PTVs, the con-
formity indices (CoI) of the 95% (CoI95%) and 98%
(CoI98%) isodoses (volume of 95% or 98% isodose divided
by PTV volume, respectively), and the homogeneity indi-
ces (HI = (D2%–D98%)/D50%, where Dx% is the dose cover-
ing x% of the PTV volume) were recorded. For the
OARs, we noted the maximal doses to the spinal cord,
medullary canal, cauda equina, sacral nerve roots, rec-
tum, bladder and bowels (including small intestine and
colon). Healthy tissue was the volume defined by the
external contour excluding the PTVs and we calculated
and collected its average dose (in Gy) and integral dose
(in J). Dosimetric data were collected in the same way
for tomotherapy plans and for proton therapy plans.
Results
Patient characteristics
Table 1 summarizes the characteristics of the patient
cohort. Mean patient age at the start of the treatment
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was 62.7 years (range, 36.7–83.1 years). Eighteen men
and 12 women were treated. Three patients had cervical,
5 had lumbar and 22 had sacro-coccygeal chordomas.
Mean interval between symptom expression and ana-
tomical or pathological diagnosis was 19.2 months
(range, 0–175 months). The disease manifested as iso-
lated pain in 18 patients (60%), vesical-sphincterian dys-
functions in 4 patients, a combination of the two in 2
patients and one sacral chordoma was detected as a result
of sub-acute cauda equina syndrome; upon diagnosis, 35%
of the 23 evaluated patients were WHO 0 (8 patients), 52%
were WHO 1 (12 patients), 9% were WHO 2 (2 patients)
and 4% were WHO 3 (1 patient) [15].
Twenty-two patients (73%) had an operation, of which
10 (45%) had osteosynthesis implants. The remaining
eight patients (27%) had only biopsy. Surgical resection
was evaluated as R0 (no microscopic residual disease) in
5 patients (23%), R1 (microscopic residual disease) in 11
patients (50%), R2 (macroscopic residual disease) in 5
patients (23%) and not classified in one patient (4%). Six
patients (27%) had second surgery evaluated as R0 for
one patient, R1 for 2 patients and R2 for 3 patients. Two
patients received neo-adjuvant treatment, one with
Imatinib and one with a combination of Imatinib and
Cyclophosphamide.
Furthermore, when our cohort was treated, proton ther-
apy for spinal and sacral chordomas was not available in
France. Referrals for proton therapy abroad were refused
because of accessibility or delay issues and technical rea-
sons related to localization. The reasons for refusal were
often multiple for a single patient. Our patient cohort was
not optimal for proton therapy as several patients were in
bad overall condition, had a very large PTV (mean 610 cc)
and/or osteosynthesis implants. Proton therapy is readily
available for patients in better general condition, and in
particular for patients that are younger than our patient
cohort (children and young adults having priority for
proton therapy as a general rule).
Tomotherapy treatment
Radiation therapy was proposed for 12 post-operative
patients (40%) with residual disease (microscopic re-
sidual R1 for 7 patients and macroscopic residual R2
for 5 patients), for 8 patients (27%) with not-operated
primary tumor, for 6 patients (20%) with relapse tumor
and for 4 patients (13%) with operated primary tumor
without residual disease R0. The median interval
between pathology and beginning of HT was 4.6 months
(range, 1.7–93.7).
Dose was prescribed to the median of the PTV, ac-
cording to the ICRU 83 recommendations [14]. OAR
dose constraints conformed to published recommenda-
tions [7, 8, 16–19]. For technical reasons, the dosimetric
treatment plans of 2 patients were not recovered and
therefore the dosimetric analysis was performed on the
remaining 28 patients. Ten patients had two PTVs:
PTV1 was the macroscopic target volume prescribed a
boost dose in addition to the dose prescribed to the
microscopic target volume PTV2. The boost volume was
defined on post-operative MRI by the residual tumor
volume. The use of simultaneous integrated boost plans
depended on the individual center’s practices. Eighteen
patients had a single PTV (PTV1). Median prescribed
doses for PTV1 were 68 Gy (range, 61.2–74 Gy) in 35
fractions (range, 25–39) with a median fraction dose of
2 Gy (range, 1.8–2.5 Gy) and for PTV2 they were 59.6 Gy
(range, 46–66.5 Gy) in 31 fractions (range, 23–35) with a
median fraction dose of 1.9 Gy (range, 1.8–2). All
patients were able to complete their treatment. The
total and fraction doses were center-dependent.
No specific adjuvant treatments were performed follow-
ing HT. At relapse, patients received different salvage in-
cluding surgery, RT and general targeted therapy (Imatinib,
Sorafenib, and Gefitinib) or chemotherapy (Doxorubicin).
Analysis of survival
The median follow-up time was 30 months (95% CI,
19.8–40). Ten patients (33%) developed a local failure.
Actuarial 1- and 2-year LC rates were 92.7% (95% CI,
Table 1 Patient characteristics
Characteristic n
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73.7–98.13) and 69.9% (95% CI, 46–84.8), respectively.
At the time of the analysis, 5 patients died due to chor-
doma evolution. Two- and 3-year OS rates were 96.7%
(95% CI, 78.6–99.5) and 90.6% (95% CI, 65.7–97.7), re-
spectively. The 1- and 2-year MFS rates were 96.5%
(95% CI, 77.9–99.5) and 76.4% (95% CI, 51.2–89.7),
respectively (Fig. 1).
Eight patients (27%) developed a metastasis (in the
order of highest to lowest frequency): bone, epiduritis,
pulmonary/pleural, cutaneous or sub-cutaneous and
muscular, inguinal and/or mediastinal adenopathies,
liver, and one exceptional salivary glands metastasis
confirmed by pathological examination.
Clinical follow-up
All patients remained clinically stable during HT. At the
time of diagnosis, 85% of the evaluated patients (23 out
of 27) experienced pain, with 70% (7 out of 10) reporting
pain ≤ 5/10 and three patients reporting pain between 6
and 7/10. At the completion of HT, 6 out of the 17 eval-
uated patients experienced no pain, 6 presented a pain
from 1 to 5/10 and 5 reported a pain between 6 and 9/
10. Retrospective data on analgesics (only available for a
few patients) showed a minor increase to level 3 analge-
sics at the conclusion of treatment (from 2 out of 8
evaluated patients at diagnosis to 6 out of 14 evaluated
patients at the end of HT).
Post-operatively, of the 21 evaluated patients, 6 (29%)
and 3 (14%) exhibited complications of Grade 2 and 3,
respectively. These complications were not aggravated
by HT. One year after HT treatment, 16 and 11% of the
evaluated patients presented vesical sphincter disorders
of Grade 2 and 3, respectively. An example of clinical
and radiological case is shown in Fig. 2.
Toxicity of tomotherapy
Radiation treatment toxicities are summarized in Table 2.
There were thirty instances of acute Grade 1 and 2 cuta-
neous and digestive toxicities. Four early Grade 3 toxic-
ities were reported. Three of them were cutaneous and
one was digestive, involving mucoid diarrhea and dehy-
dration requiring hospitalization. Two late Grade 3 tox-
icities were reported. One case of cutaneous necrosis
and one case of radiation proctitis were observed. The
latter was responsible for rectal bleeding which required
hospitalization and endoscopic treatment by Plasma
Argon. No radiation myelitis or radiation neuropathy
cases were reported. No Grade 4 or 5 toxicities were
observed. No definitive interruption of treatment due to
toxicity was observed.
Dosimetric data
For PTV1, the mean volume was 610 cc (range, 7–2211),
median CoI95% was 1.25 (range, 0.83–4.13) for tomother-
apy and 1.08 (range, 0.88–5.97) for proton therapy,
median CoI98% was 1.05 (range, 0.64–2.12) for tomother-
apy and 0.93 (range, 0.71–1.62) for proton therapy, and
median HI was 0.13 (range, 0.03–0.62) for tomotherapy
and 0.07 (range, 0.03–0.91) for proton therapy. For PTV2,
the mean volume was 659 cc (range, 27–1894), median
Fig. 1 Survival probabilities with the 95% CI shown as the shaded area: (a) local control, (b) overall survival, (c) metastasis free survival and (d)
progression free survival
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CoI95% was 1.49 (range, 0.89–4.12) for tomotherapy and
1.1 (range, 0.87–3.34) for proton therapy, median CoI98%
was 1.23 (range, 0.63–3.59) for tomotherapy and 0.98
(range, 0.42–3.15) for proton therapy, and median HI was
0.18 (range, 0.06–0.49) for tomotherapy and 0.09 (range,
0.03–0.27) for proton therapy. Median values of the
minimal, maximal and mean doses to OARs are given in
Table 3 for tomotherapy and proton therapy plans. In
general, we observed that minimal and mean doses were
lower in proton therapy. This is due to the lower number
of beams that are needed for sufficient coverage of the
target volume with the prescribed dose (Fig. 3).
Integral dose is significantly lower in proton treatment
plans, as illustrated in Fig. 4. The median integral dose
for the 28 patients considered in the dosimetric com-
parative study was 70 J for proton plans and 240 J for
tomotherapy plans. Overall, proton dosimetries are
superior to tomotherapy dosimetries, if one ignores the
presence of metal implants, which tend to create hot
and cold spots inside the PTV in proton plans. The only
other exception we found to this conclusion were cases
where the PTV completely encloses the spinal cord and
in our experience, tomotherapy plans seem to better
spare the spinal cord in those situations.
Discussion
Different RT techniques have been evaluated for the treat-
ment of spine chordomas and are listed in Table 4. In the
case of photon beams, these included 3D conformal RT
(3DCR) [20, 21], IMRT [22, 23] and stereotactic [24, 25]
delivery. When compared to these techniques, hadron
therapy with protons [4, 5, 26–30] or carbon ions [6, 31]
showed better results in LC and survival.
The present study has a median follow-up of
30 months. A subsequent updating of data will allow a
longer median follow-up and better knowledge of the
effectiveness and longer-term toxicity of the technique.
Our 2-year LC rate of 70% is inferior to the rates
reported in the best series of proton or carbon ion ther-
apy, which have 3-year and 5-year rates of 90 and 85%,
respectively. Our 3-year OS rate of 90.6% is comparable
to proton and carbon ion series (Table 4).
Twenty seven percent of the patients in our study pre-
sented a metastatic evolution of their disease. This result
is comparable to other series in the literature with
longer median follow-up times.
Fig. 2 The case report of a 61 year-old male patient of the study,
with an inoperable 8-cm sacrococcygeal chordoma treated by
helical tomotherapy at a dose of 70 Gy. Treatment tolerance was
excellent, with no acute or late toxicities and good efficacy on pain
management. We note a regression of the tumor seen in MRI
evaluations before helical tomotherapy (top line), at 1.5 years
(middle line) and at 3 years (bottom line), in all directions mainly
in the anterior-posterior plane from 83 mm to 38 mm (left: T2
sequences; right: axial T1 sequences after Gadolinium injection)
Table 2 Radiation treatment toxicities
Acute toxicities Late toxicities
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Skin 9 9 3 5 1 1
GIa 9 3 1 0 0 1
Urinary 4 0 0 0 0 0
Neurological 1 1 0 0 2 0
aGI gastro-intestinal
Table 3 Median values of minimal, maximal and average OAR
doses for tomotherapy (T) and proton therapy (P)
Dmin (Gy) Dmean (Gy) Dmax (Gy)
Spinal cord, T 2.3 11.3 30.6
Spinal cord, P 0 15.1 42.8
Medullary canal, T 1.8 13.4 50.9
Medullary canal, P 0 8.1 57.7
Lumbosacral canal, T 1.8 25.0 49.4
Lumbosacral canal, P 0 13.3 51.9
Bladder, T 5.4 23.3 54.8
Bladder, P 0 0.1 15.4
Rectum, T 3.6 31.5 66.2
Rectum, P 0 13.2 69.1
Digestive system, T 1.1 17.4 63.4
Digestive system, P 0 1.5 64.2
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Conventional RT, up to 40–60 Gy doses, results in a
5-year LC rate of only 10–60% [3]. Terezakis et al. [23]
reported that IMRT photon RT of 66 Gy resulted in a 2-
year LC of 65% and a 2-year global survival of 79%,
which is comparable to our results. Yamada et al. [24]
used stereotactic RT in a single fraction of 24 Gy and
obtained tumor regression or stability in 95% of patients
at 2 years. Delaney et al. delivered up to 77.4 Gy relative
biological effectiveness (RBE) to gross disease [4, 5] and
found that proton therapy resulted in a 5-year and 8-
year LC rates of 81 and 74%, respectively. Imai et al. [6]
treated 38 inoperable sacral chordomas with carbon ions
and observed a 5-year LC rate of 89%.
For various reasons, our LC rate is lower than reported
in other series. Firstly, 73% of our cases were voluminous
sacral localizations and this is associated with a less favor-
able prognosis. Secondly, 87% of our patients had residual
disease when treated by HT. Staab et al. [30] reported that
the 5-year LC rate decreased from 66 to 47% in the
macroscopic residual cases. Similarly, Rutz et al. [28]
reported that when the tumor residual exceeded 30 cc, the
global- and progression-free survival results were statisti-
cally lower than in the case of smaller volumes. Thirdly,
our patients had large target volumes (mean and median
PTV values were 640 cc and 421 cc, respectively).
Fourthly, osteosynthesis material was present in one-third
of the patients. Out of the 10 local failure patients, one
patient had a PTV larger than 610 cc and 2 patients pre-
sented osteosynthesis and 2 patients had both large PTV
Fig. 3 Comparison of a proton treatment plan (left) and a tomotherapy treatment plan (right) for the same patient. Top panel: the color wash
indicates the volume covered by 1 Gy. Bottom panel: DVHs for the plans above
Fig. 4 Comparison of integral doses for the 28 patients for
tomotherapy vs proton therapy plans
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and osteosynthesis. Finally, we note that two-thirds of our
patients were not eligible for proton therapy because of
their altered clinical condition mainly due to the evolution
of their disease. The retrospective nature of data collection
did not allow us to obtain any specific clinical data which,
therefore, limits the clinical description of patients.
Of note, osteosynthesis material could be an important
limitation for proton therapy. For instance, Staab et al.
[30] report on proton therapy showed the 5-year LC rate
decrease from 100 to 30% when osteosynthesis material
was present. Similarly, in Rutz et al. study [28], implants
were also associated with a lower LC rate (p = 0.034).
The authors proposed several factors that may explain
the decrease in LC. Among major concerns, they noted
that protons create important dose heterogeneity in the
vicinity of the material with cold and hot spots, which
requires a reduction of the fraction dose and/or total
dose [28]. In addition, Verburg et al. [32] have demon-
strated that osteosynthesis material can introduce
uncertainties of up to 1 cm in proton range. Finally,
osteosynthesis material complicates the delineation of
volumes because of artifacts in the planning CT.
The clinical characteristics of our patients were com-
parable to those stated in the literature [1, 2]. Symptoms
were dominated by pain, similar to other series [33]. We
recorded partial or total pain alleviation in the available
data. However, some data were missing as pain was not
always reported. Vesical-sphincterian dysfunctions were
not aggravated by HT.
In the majority of cases, HT was delivered without
interruption due to toxicity. Only six cases of Grade 3
toxicity were recorded. In our cohort, we did not ob-
serve any Grade 4 or 5 toxicity, radiation myelitis or ra-
diation neuropathy (including the roots of cauda
equina). In general, more severe toxicities are reported
in proton and carbon ion series. Delaney et al. [4, 5]
observed three sacral neuropathies, following 76.6–
77.4 Gy RBE and reported a complication risk of 13%
Table 4 Results of the main series of radiotherapy of chordomas of the mobile spine and the sacrum













X 48: 23 (S) 20 (SB) 5 (MS) 50/40/24 2/1/8 54% at 5 Catton
et al. [19]
20% at 10




X (IMRT) 34 (S) 66 [1.8–2] 4.5 27% at 5 70% at 5 9% Zabel-du Bois
et al. [21]
(80% at 5)
X (IMRT) 7 (MS) 66 [1.8–2] 1.45 65% at 2 Terezakis
et al. [22]
X (SRS) 24: 10 (S) 7 (C) 4 (T) 3 (L) 18–24 [18–24] 2 95% at 4 67% at 4 12.5% Yamada
et al. [23]
X (SBRT) 18: 8 (MS) 7 (SB) 3 (S) 35 [6–8] 3.8 59.1% at 5 74.3% at 5 Henderson
et al. [24]
1H +/−X 29 (MS) 76.6 1.8 7.3 84% at 5 87% at 5 Delaney
et al. [4, 5]
24: 19 (S) 2 (C) 1 (T) 2 (L) 77.4 [1.8–2.5] 4.7 90.4% at 3 79.8%
at 5
78.1% at 5 Chen
et al. [25]
25 (MS, S) 70.4 1.8 2.65 73.3% at 5 64.3% at 5 Wagner
et al. [26]
26: 9 (C) 2 (T) 8 (L) 7 (S) 72 [1.8–2.5] 2.9 86% at 3 84% at 3 Rutz
et al. [27]
19: 12 (SB) 5 (C) 1 (L) 1 (S) 74 [1.8–2] 3.8 81% at 5 89% at 5 Rombi
et al. [28]
40: 16 (C) 4 (T) 10 (L) 11 (S) 72.5 [1.8–2] 3.6 62% at 5 80% at 5 Staab et al.
[29]
12C 38 (S) 70.4 [4.4–4.6] 6.7 95% at 3 89% at
5
95% at 3 Imai et al. [6]
86% at 5
17 (S) 70.4 [4.4–4.6] 4.1 100% at 5 53.3% at 5 14% Nishida
et al. [30]
SB skull base, T thoracic, L lumbar, S sacral, MS mobile spine, C cervical
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for Grade 3–4 at 8 years. Chen et al. [26] found 8 sacral
fractures, one secondary cancer, one foot drop, one
erectile dysfunction and one loss of perineal sensation.
Rutz et al. [28] reported four severe complications: one
Grade 2 sensory neuropathy, one Grade 3 subcutaneous
necrosis, one Grade 3 osteonecrosis and one Grade 5
secondary cancer. Imai et al. [6] described two late Grade
4 cutaneous reactions which required skin grafts, and six
neurological complications, of which one was an incom-
plete transient aggravation of sciatic nerve paralysis. The
small number of patients did not allow us to show signifi-
cantly that the dose per fraction or the total dose were
factors for local control, toxicity risk or relapse.
Conclusion
This multicentric, retrospective study included an im-
portant series of patients, considering the rarity of the
pathology and the cohorts discussed in other series. To
our knowledge, this is the largest series of chordomas
treated by HT. A longer follow-up is necessary to assess
long-term survival and late toxicities. Hence, we con-
clude that HT permitted the delivery of high tumor
doses with acceptable toxicities and can be used in the
management of spine chordomas when hadron therapy
is not possible.
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